Rapid, accurate, and inexpensive genome sequencing promises to transform medical care.
Introduction
The advent of next-generation sequencing that is quick, accurate, and affordable has promised to usher in a new era of genomic medicine. However, a critical issue facing the development of sequencing-based tests is the interpretation of novel genetic variants in terms of their probability of causing disease. This is a particularly pressing problem with so-called "clinically relevant genes", including the cystic fibrosis transmembrane conductance regulator (CFTR) gene, for which DNA changes are known to impact phenotype, but for which the map of how each genotype affects the clinical phenotype is incomplete. Differentiating "benign" from "pathogenic" genetic variants is challenging, and often physicians are left with the unsatisfying and inconclusive result that their patient carries a "Variant of Unknown Significance" (VUS).
Despite recent advances in applying machine learning techniques to problems in biomedicine, existing computational approaches to variant classification all suffer from low overall accuracy rates.
For example, SIFT 1 and PolyPhen-2 2 are among the most widely used algorithms, but each has an accuracy of less than 70% 3 . Their poor performance limits the clinical utility of these tools in determining whether a novel genetic variant is actually related to the disease of interest. We aimed to improve the performance of computational interpretation tools by developing a gene-specific metapredictor, focusing on the CFTR gene, which combines information from the most promising available tools supplemented with protein structure and stability features, physicochemical properties of mutated residues, and allele frequency information.
To develop this computational model, we focused our analyses on variants in the coding region of the CFTR gene. Despite recent progress in both sequencing and analysis techniques, interpreting the functional effect of variants in non-coding regions remains problematic due to insufficient training data.
Therefore, to maximize the prediction capability of our model, we are initially focusing solely on the variants that are most likely to be relevant in terms of disease association, due to their relatively clearer relationship to protein structure.
Many bioinformatics methods have been developed for predicting the effect of missense mutations, which vary by the number of features included and the type of machine learning algorithm employed. The most advanced tools typically rely on amino acid sequence, protein structure, and evolutionary conservation for their prediction. For example, while SIFT relies solely on conservation, measured via multiple sequence alignment, PolyPhen-2 includes both sequence and structure-based features for prediction. The structure-based features in this context are used to describe the physical environment of the mutation, and include predictors such as solvent-accessible surface area, hydrophobic propensity, and the "mobility" of the atom. Another missense pathogenicity predictor, MutPred 4 , uses a much larger set of structural parameters, including secondary structure, stability and intrinsic disorder, transmembrane and coiled-coil structure. In addition, MutPred utilizes functional properties of the protein, such as sites of post-translational modification, catalytic and DNA-binding residues. MutPred outperforms SIFT by 7% in the area under the ROC curve (AUC), and, more importantly, in addition to pathogenicity score can provide information about the molecular basis of the disease.
While SIFT, PolyPhen-2 and MutPred are trained using data from across the genome, genespecific pathogenicity prediction methods have also been developed. For example, Masica et al. 5 created a CFTR-specific prediction algorithm called Phenotype-Optimized Sequence Ensemble (POSE). In contrast to methods utilizing multiple sequence alignment, POSE tries to iteratively construct an optimized sequence ensemble based on the performance of the scoring function, which uniquely integrates evolutionary conservation with physicochemical properties of the amino acids (such as charge, presence of aromatic or aliphatic group, hydrogen bond donor or acceptor, and signals for glycine and proline residues). POSE achieves a performance of 84%, as measured by AUC on a training set of 103 CFTR variants, and importantly, the method displayed improved specificity when compared to tools trained genome-wide, implying a higher accuracy potential for methods trained on single genes.
Combining existing methods into a single predictor has proven to yield increased accuracy 6, 7 .
Successful examples of such meta-predictors, therefore, suggest that the separate methods used for prediction of variant-disease associations are orthogonal, and represent different biologically relevant relationships. The advantage of the machine learning classifier is its ability to integrate these orthogonal measures to identify predictive signatures of pathogenicity. Thus we are employing such a combination strategy in developing our CFTR-specific meta-predictor.
In addition to combining outputs from several existing prediction tools, we are also adding other useful features into out meta-predictor. Importantly, we integrate protein stability measures into our pathogenicity predictor. Protein stability is a fundamental property that affects function, activity, and regulation of biomolecules. Conformational changes are required for many proteins' function, implying that conformational flexibility and rigidity must be finely balanced. Incorrect folding and decreased stability are two of the major consequences of missense mutations, which can lead to disease. Protein stability is measured by the folding free energy change upon mutation, which is calculated as the difference in free energy between the folded and unfolded protein states 8 
Materials and Methods

Variants data collection
We utilized various data sources, both publically available and internal, to collect known protein coding variants in the CFTR gene ( 16 . In addition we also included variants used for training and testing the previously described POSE method, which was trained directly on CFTR 5 . Overall, 1,899 protein coding CFTR variants have been collected, of which the majority (>60%) are missense variants (Fig. 1A) . Clinical significance (pathogenic, benign, variant of unknown significance (VUS)) was merged from different sources, and conflicting entries (reported as pathogenic by one source and benign by other) were considered as VUSs. Since the ExAC database does not report variants' pathogenicity, all the CFTR variants from ExAC were considered as VUSs. As expected, only a small portion of collected variants had pathogenicity evidence (14% pathogenic, 7% benign) (Fig. 1B) , with the majority (~80%) having unknown significance.
The full dataset of 1,899 CFTR variants with clinical significance from corresponding sources can be found on GitHub (https://github.com/rychkova/CFTR-MetaPred).
Variants annotation
Our meta-predictor is built by combining outputs from a number of the available prediction tools and supplementing them with information extracted from protein structure and allele frequency ( 9, 10 for each of the stability predictor, which gave rise to six total stability features.
We further created several structural parameters based on the information in UniProt 23 and 3D
CFTR protein structure, such as protein domains (extracellular loops, nucleotide binding domain 1 or 2 (NBD1 or NBD2), transmembrane domain 1 or 2 (TMD1 or TMD2), R domain), nucleotide binding residues, topology (cytoplasmic, transmembrane, or extracellular protein parts), regions of posttranslational modification (phosphorylation, glycosylation, palmitoylation, or ubiquitination sites), and involvement in protein-protein interaction (PPI_score). Our PPI_score for each residue is based on the number of times each residue is present in the motifs known to be important for protein-protein interaction and CFTR regulation. Information about protein-protein interaction motifs known for CFTR is based on the literature, and summarized in Table S1 . On top of these we added information about membrane contacting residues by building a simplified membrane model around the protein (using Coarse Grained model building tool in Molaris 24 ), and selecting neighboring to membrane atoms residues in PyMol 25 . Similarly, we created a feature with channel contacting residues, by inserting a straight helix into the channel and selecting neighboring residues in PyMol.
We used DSSP tool 26 to calculate change in solvent accessible area and hydrogen bond energy of the full protein as well as single residue upon mutation. Structural models of all the 1,210 mutant proteins (missense variants plus initiator codon variants) were obtained with Eris program 20 using the default fixed-backbone method. Change in several physicochemical properties of residue due to mutation was estimated based on the information in the AAindex dataset 27 (charge, polarity, volume, partition energy, hydrophobicity, proline signal (mutation to/from proline)).
The full dataset with 35 annotation features collected for all the CFTR missense variants can be found on GitHub (https://github.com/rychkova/CFTR-MetaPred).
Machine learning model training
To build the machine learning model, we utilized the statistical software program R with the library package caret 28 . To find the best performing algorithm, we tested several available methods:
regularized logistic regression (GLM), regularized discriminant analysis (RDA), support vector machine (SVM), stochastic gradient boosting (tree boosting method) (GBM), and random forest (RF). The description of all the methods can be found in ref 29 . Of the 1,210 missense and initiator codon variants we annotated with 35 features, 295 unique variants had known clinical significance (161 pathogenic, 134 benign). We performed data preprocessing step by converting all the categorical features into numeric values, converting all the values into Z-scores, and imputing data with KNN method. It should be noted that a considerable amount of missing allele frequency data did not allow for a KNN imputation of this category, thus we used a dummy value of -1 for all the missing allele frequencies. We divided our dataset into training and testing sets with a ratio of 70/30. Five different models were built on the training set using five-fold cross validation for resampling, and the performance was measured on the test set. We have also estimated the performance of all the separate 35 features on the training set and compared it with the machine learning models.
Results
Performance of all the five machine learning models we built and the 35 separate features can be found in Tables 3 and 4 , respectively. Of the five models tested, RF showed the highest accuracy (77%).
Based on the AUC values, RF model outperformed all the other machine learning models (AUC RF = 85%) ( Fig. 2A) , and it also improved over other popular tools, such as CADD (AUC CADD.RawScore = 70%), SIFT (AUC SIFT = 63%), and PolyPhen-2 (AUC PolyPhen2 = 60%) (see Fig. 2B and Table 4 ). Out of the 35 separate features, AF showed the best performance (AUC AF = 73%) (Fig. 2B) . AF, Density, MutPred, POSE, and SIFT were selected as the most important features by the RF model (see Fig. 3 and Table S2 ). Interestingly, when looking at the features by their class (as defined in Table 2 ), features based on allele count (AF and Density) seem to be the most significant ones ( From six physicochemical property features we derived from AAindex database (volume_change, polarity_change, partition_energy_change, hydrophobicity_change, charge_change, pro_signal), change in residue volume upon mutation seems to be the most important one.
To confirm our predictor's validity, we have also examined how predicted pathogenicity probability correlates with existing clinical and functional data. We used previously measured mean chloride conductance values 30 ( Fig. 4A and Table S3 ) and sweat chloride data collected on patients at
The Stanford CF Center ( Fig. 4B and Table S4 ). The sweat chloride correlation analysis was restricted to patients heterozygous for p.F508del to reduce the variability due to different allele combinations.
Both characteristics correlate well with the pathogenicity scores obtained using our RF classifier, with chloride conductance, which is a more direct measure of channel function, displaying the higher as well. While our newly developed meta-predictor is not intended to uncover the molecular mechanisms of pathogenicity, it can help in prioritizing novel and rare genomic variations, identified through sequencing, for future functional studies. In addition, additional functional data may help to suggest potential cellular mechanism of the disease and allow for more accurate selection of specific therapies, as well as identify patients suitable for particular clinical trials.
The predictor described here could only be used to estimate a pathogenicity probability of missense variants, and its extension to other types of variants is somewhat less straightforward. The issue arises from the limited applicability of the predictors and structural features that we have utilized to build the model to classes of variants outside the missense category. In particular, only the methods PROVEAN and CADD can be applied to insertions and deletions, while nonsense, splicing, and synonymous mutations can be assessed by CADD only. To extract structural features, the structure of the mutated protein must be available, which is problematic for insertions and deletions that can cause large changes in structure. Moreover, the small set of TPs and TNs available for non-missense variant types limits our ability to train a similar meta-predictor, though allele frequency could in principle be used for any variant type. This again highlights the importance of additional functional measurements, which can be used alone or in combination with a few available computational features to establish the pathogenic status of all other types of variants.
By combining multiple levels of knowledge about CFTR structure and function, and training the machine learning model on the set of known pathogenic and benign variants, we created a CFTRspecific pathogenicity predictor tool of higher accuracy, which we hope may aid in interpreting and prioritizing CFTR variants, and be further evaluated by functional studies. This model's predictions will be hosted on the ClinGen Consortium database, to make it easily available to other CF researchers and to demonstrate the feasibility of such an approach for a variety of Mendelian diseases. Overall, this report can be used as a description and model of the general strategy for developing a pathogenicity predictor of improved accuracy, so that feasibility of similar approaches may be evaluated for other genes.
Description of Supplemental Data
Supplemental Data include notes on data collection from Stanford internal resources (CF Center and MPL) and four tables. Tables   Table 1. CFTR variants data collection Variants data have been collected from six data sources, including external publicly available data and internal data from Stanford-affiliated laboratories. Total number of unique variants collected is 1,899. * The Stanford MPL database that we used include variants identified during clinical CF testing at the lab, and laboratory-curated CFTR variants from various public datasources, including the CF Mutation Database, the CFTR2 database, National Center for Biotechnology Information's dbSNP, and Ensembl. TPR -true positive rate, TP -number of true positives, P -total number of positives (true positives + false positives), TNR -true negative rate, TN -number of true negatives, N -total number of negatives (true negatives + false negatives). Accuracy = (TP+TN)/(P+N). 
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